SOBI 📈 Swedish Orphan Biovitrum - Overview

Swedish Orphan Biovitrum AB (publ) operates as a fully integrated biotechnology company, focusing on the research, development, manufacturing, and distribution of pharmaceuticals across various therapeutic areas, including haematology, immunology, and specialty care. The company's product portfolio is diverse, with a range of treatments for rare and serious diseases. For instance, it offers Alprolix for haemophilia B, a genetic disorder that impairs the body's ability to clot blood, and Elocta for haemophilia A, another bleeding disorder. Additionally, the company provides Aspaveli for the treatment of paroxysmal nocturnal haemoglobinuria, a rare and potentially life-threatening disease.

The company's product line also includes Doptelet, used to treat thrombocytopenia, a condition characterized by low platelet counts, and Gamifant, which is designed to treat hemophagocytic lymphohistiocytosis, a rare and aggressive disease of the immune system. Furthermore, Swedish Orphan Biovitrum AB (publ) offers VONJO for the treatment of myelofibrosis, a type of bone marrow disorder, and Zynlonta, used to treat certain types of aggressive malignant diseases. Other notable products include Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, and Still's disease, as well as Orfadin, which is used to treat hereditary tyrosinaemia type-1, a rare genetic disorder.

Swedish Orphan Biovitrum AB (publ) also engages in the development and manufacturing of drug substances for other pharmaceutical companies. For example, it develops ReFacto AF/Xyntha for Pfizer, used to treat haemophilia A, and Nirsevimab, a treatment for respiratory syncytial virus. The company has established strategic collaborations with several major pharmaceutical companies, including Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. These partnerships enable the company to expand its product portfolio, enhance its research and development capabilities, and improve its global reach.

With a history dating back to 1939, Swedish Orphan Biovitrum AB (publ) has established itself as a significant player in the biotechnology industry. The company is headquartered in Solna, Sweden, and its common stock is listed on the stock exchange. The company's website provides detailed information about its products, research and development activities, and corporate governance. As a leading biotechnology company, Swedish Orphan Biovitrum AB (publ) is committed to developing and delivering innovative treatments for rare and serious diseases, improving the lives of patients worldwide.